{"filings":[{"id":722209,"accession_number":"0001104659-26-067509","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-05-28T20:15:25+00:00","items":["5.07"],"status":"ready","headline":"Merck shareholders elect all 13 directors, approve say-on-pay, reject three proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 director nominees elected; Patricia Russo received 1.637B for (highest opposition at 217M votes against).","Say-on-pay passed: 1.730B for, 109M against, 284M broker non-votes.","Ratification of PwC as auditor for 2026 approved: 2.012B for, 126M against.","Three shareholder proposals on DEI risks, healthcare gaps, political contributions all rejected; each received <5% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609956,"accession_number":"0001628280-26-037738","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-05-22T20:21:18+00:00","items":["8.01","9.01"],"status":"ready","headline":"Merck closes $6B multi-tranche debt offering with maturities from 2028 to 2056","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $6B aggregate principal across seven tranches: floating rate notes due 2028 and fixed-rate notes at 4.300%-5.850% due 2028-2056.","Tranches include $1.5B 5.200% notes due 2036 and $1B 5.850% notes due 2056.","Offering closed May 22, 2026 via underwritten public offering under existing shelf registration.","Use of proceeds not disclosed; debt issuance adds to long-term balance sheet leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97890,"accession_number":"0001104659-26-052081","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck reports Q1 GAAP loss per share of $1.72 on $16.3B sales; narrows and raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS loss of $1.72; Non-GAAP EPS loss of $1.28, both include $3.62/share charge for Cidara acquisition.","Total sales $16.3B, +5% YoY; KEYTRUDA sales $8.0B (+12%), WINREVAIR $525M (+88%).","Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS guidance raised to $5.04-$5.16.","Announced agreement to acquire Terns Pharmaceuticals; one-time charge ~$5.8B (~$2.35/share) not in guidance.","Animal Health sales $1.8B (+13%); multiple regulatory approvals including IDVYNSO for HIV."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":16286000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113075,"accession_number":"0001104659-26-009495","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q4 Non-GAAP EPS $2.04 (+19% YoY); FY2026 guidance $5.00-$5.15 on Cidara charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 sales $16.4B (+5% GAAP EPS $1.19, Non-GAAP EPS $2.04).","Full-year sales $65.0B; Non-GAAP EPS $8.98 (+17% YoY).","KEYTRUDA $31.7B (+7%); WINREVAIR $1.4B; GARDASIL $5.2B (-39% on China weakness).","FY2026 sales guidance $65.5-$67.0B; Non-GAAP EPS $5.00-$5.15 includes ~$3.65 Cidara charge.","Acquired Verona Pharma and Cidara; 18 positive Phase 3 trials in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":7.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":65011000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129479,"accession_number":"0001628280-25-055388","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Merck closes $8.0B multi-tranche debt offering across eight series","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total $8.0B includes Floating Rate Notes due 2029 ($500M), 3.850% Notes due 2029 ($750M), 4.150% due 2031 ($1B), 4.450% due 2032 ($1B).","Also $1.5B 4.750% Notes due 2035, $750M 5.500% due 2046, $1.5B 5.550% due 2055, and $1.0B 5.700% due 2065.","Offering closed December 4, 2025 under existing shelf registration statement (333-278066).","Proceeds not specified; notes are senior unsecured obligations issued under indenture dated Jan. 6, 2010."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129478,"accession_number":"0001104659-25-103974","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q3 GAAP EPS $2.32, non-GAAP $2.58; raises full-year non-GAAP EPS guidance to $8.93-8.98","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total sales $17.3B (+4% YoY, +3% ex-FX); GAAP net income $5.8B, non-GAAP $6.4B.","KEYTRUDA sales $8.1B (+10%); WINREVAIR $360M (+141%); GARDASIL down 24% to $1.7B.","Full-year 2025 sales guidance raised to $64.5-65.0B; non-GAAP EPS raised to $8.93-8.98.","Completed acquisition of Verona Pharma (OHTUVAYRE) in October 2025.","FDA approved KEYTRUDA QLEX subcutaneous injection for all solid tumor indications."],"consensus_eps_estimate":null,"consensus_eps_actual":6.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":48611000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146044,"accession_number":"0000310158-25-000047","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Merck closes $6B multi-tranche debt offering: floating-rate notes due 2027 to 5.700% notes due 2055","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offered $500M floating rate notes due 2027, $750M 3.850% notes due 2027, $750M 4.150% notes due 2030.","Offered $1B 4.550% notes due 2032, $1.75B 4.950% notes due 2035, $1.25B 5.700% notes due 2055.","Total aggregate principal amount of the offering is $6 billion, closed on September 9, 2025.","Proceeds use not specified; offering was underwritten public under existing shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146043,"accession_number":"0001104659-25-071380","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Merck reports Q2 2025 sales of $15.8B, down 2%, and announces $3B restructuring program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total worldwide sales $15.8 billion, down 2% nominally and ex-forex vs Q2 2024; KEYTRUDA sales $8.0 billion, up 9%.","GAAP EPS $1.76, Non-GAAP EPS $2.13; includes $0.07 per share charge for Hengrui Pharma license agreement.","GARDASIL/GARDASIL 9 sales $1.1 billion, decline of 55% primarily due to lower demand in China.","Approved 2025 Restructuring Program with cumulative pretax cost ~$3.0 billion, expected annual savings ~$1.7 billion by end of 2027.","Announced agreement to acquire Verona Pharma for ~$10 billion, adding COPD treatment Ohtuvayre; expected close Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":3.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":31335000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164346,"accession_number":"0001104659-25-054131","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Merck shareholders re-elect all 13 directors, defeat four shareholder proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 director nominees elected; Patricia Russo received lowest support with 1.59B for and 250.6M against.","Non-binding say-on-pay passed with 1.67B votes for (84.8% of votes cast excluding broker non-votes).","Ratification of PricewaterhouseCoopers as auditor for 2025 approved with 2.02B votes for.","Shareholder proposals on human rights assessment, tax transparency, DEI in pay incentives, and civil liberties report all defeated by large margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164345,"accession_number":"0001104659-25-038301","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck reports Q1 2025 EPS $2.01, sales $15.5B; GARDASIL plunges 41% on China weakness","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $2.01 (up 7% YoY); non-GAAP EPS $2.22 (up 7%); revenue $15.5B (-2% reported, +1% ex-FX).","KEYTRUDA sales $7.2B (+4% reported, +6% ex-FX); WINREVAIR $280M post-launch; Animal Health +5%.","GARDASIL sales fell 41% to $1.3B on lower China demand; ex-China sales grew 14% (16% ex-FX).","FY2025 non-GAAP EPS guidance revised to $8.82-8.97 from $8.88-9.03 due to $0.06 charge for Hengrui license.","Tariffs expected to add ~$200M cost in 2025; full-year sales outlook unchanged at $64.1B-$65.6B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":15529000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182102,"accession_number":"0001104659-25-008863","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q4 2024 sales $15.6B (+7% YoY); GAAP EPS $1.48, Non-GAAP $1.72; FY2025 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 worldwide sales $64.2B (+7% YoY; +10% ex-FX).","Q4 GAAP EPS $1.48; Non-GAAP EPS $1.72 (includes $0.23 charge for licensing).","KEYTRUDA full-year sales $29.5B (+18% YoY; +22% ex-FX).","WINREVAIR full-year sales $419M; GARDASIL declined 3% to $8.6B on lower China demand.","FY2025 guidance: sales $64.1-65.6B; Non-GAAP EPS $8.88-9.03 (incl. ~$0.09 LaNova charge)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":64168000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198758,"accession_number":"0001104659-24-122027","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Lal Karsanbhai (Emerson CEO) elected to Merck board; effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lal Karsanbhai, president and CEO of Emerson Electric, elected to Merck board effective January 1, 2025.","He will serve on Audit and Governance committees and stand for election at May 2025 shareholder meeting.","Merck board expands to 13 members with addition; compensation per non-employee director practices.","Board also adopted amended by-laws updating indemnification provisions; other non-substantive changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198757,"accession_number":"0001104659-24-112841","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q3 2024: GAAP EPS $1.24, Non-GAAP $1.57; Sales $16.7B (+4% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total worldwide sales $16.7B, up 4% (7% ex-FX). GAAP EPS $1.24; Non-GAAP EPS $1.57.","KEYTRUDA sales $7.4B (+17% / 21% ex-FX). WINREVAIR sales $149M, gaining momentum.","FY2024 guidance narrowed: sales $63.6B-$64.1B; Non-GAAP EPS $7.72-$7.77, includes $0.24/share net charge from Curon and Daiichi Sankyo deals.","R&D expenses surged 77% to $5.9B, driven by $1.35B EyeBio acquisition and $750M Curon asset purchase.","GARDASIL/GARDASIL 9 sales fell 11% due to lower China demand; Animal Health up 6% (11% ex-FX)."],"consensus_eps_estimate":null,"consensus_eps_actual":5.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":48544000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214793,"accession_number":"0001104659-24-083722","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q2 2024: revenue $16.1B (+7% YoY); raises sales outlook but lowers EPS guidance on EyeBio charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $16.1B (+7% YoY, +11% ex-FX); GAAP EPS $2.14, Non-GAAP EPS $2.28; KEYTRUDA sales $7.3B (+16%).","Full-year 2024 sales outlook raised to $63.4-64.4B (from $63.1-64.3B); Non-GAAP EPS guidance lowered to $7.94-8.04 (from $8.53-8.65) due to $1.3B EyeBio acquisition charge.","WINREVAIR generated $70M in Q2 sales; over 1,000 patients treated since U.S. launch in March 2024.","Completed acquisitions of EyeBio and Elanco's Aqua Business in July 2024; $0.51/share EPS impact from EyeBio.","CDC's ACIP unanimously recommended CAPVAXIVE; positive EU CHMP opinion for WINREVAIR in PAH."],"consensus_eps_estimate":null,"consensus_eps_actual":4.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":31887000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233937,"accession_number":"0001628280-24-025800","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Merck subsidiary MSD Netherlands closes €3.4B offering of senior notes across four tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€850M each of 3.250% notes due 2032, 3.500% notes due 2037, 3.700% notes due 2044, 3.750% notes due 2054.","Notes are fully and unconditionally guaranteed on an unsecured senior basis by Merck & Co., Inc.","All 12 director nominees elected with 84.78%-99.49% of votes cast; advisory say-on-pay approved at 93.50%.","Shareholder proposals on written consent, censorship, and workforce civil liberties all defeated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233936,"accession_number":"0001104659-24-051517","cik":310158,"company_name":"Merck & Co., Inc.","ticker":"MRK","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Merck Q1 sales up 9% to $15.8B; raises FY2024 sales and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $1.87 (+68% YoY); Non-GAAP EPS $2.07 (+48% YoY). Sales $15.775B (+9%, +12% ex-FX).","Keytruda sales grew 20% to $6.9B; Gardasil sales up 14% to $2.2B on strong China demand.","Full-year 2024 sales outlook raised to $63.1-$64.3B; Non-GAAP EPS outlook raised to $8.53-$8.65.","Received FDA approval for WINREVAIR (PAH); closed Harpoon acquisition with $656M charge.","Proposed acquisition of Elanco's aqua business to broaden animal health portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":15775000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":296971696445.79755,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}